MAPT and early-onset autosomal dominant Alzheimer disease: One of the most promising ASOs, MAPTRx, targets the microtubule-associated protein tau (MAPT) mRNA to reduce tau protein, accumulation of which is correlated with Alzheimer’s disease progression.